Global and United States Companion Diagnostics Market Report & Forecast 2023-2029

Report ID: ARS3201 | Category: Healthcare | Pages: 96 | Format: PDF | Published Date: September 07,2023

Request Sample Enquiry before buying Ask For Discount

Single User-$4350.00 Multi User-$6300.00

Report Description
View Table of Contents

Report Summary

The research time span covered by the report is from 2018 to 2029; it provides an overview of the Global Companion Diagnostics Market and also provides a deeper in-depth segmentation of the market by regions, product type and downstream industries.

The global Companion Diagnostics market size in 2022 is 5590.0 million US dollars, and it is expected to be XX million US dollars by 2029, with a compound annual growth rate of 11.90% expected in 2023-2029.

MARKET COMPETITIVE LANDSCAPE:
The main players in the Companion Diagnostics market include Abbott Laboratories Molecular Inc. (U.S.), Agilent (Dako Denmark A/S) (U.S.), ARUP Laboratories Inc. (U.S.), BioMerieux (France), and Danaher Corporation (Leica Microsystems) (Germany). The share of the top 3 players in the Companion Diagnostics market is XX%.

REGION SHARE:
The report covers the market size information of North America, Europe, Asia Pacific, Latin America, Middle East and Africa, and North America accounted for XX%, Europe accounted for XX% of Companion Diagnostics market, and Asia Pacific accounted for XX%.

SEGMENT OVERVIEW:
The report segments the market by Type and Application. Assays accounted for XX% of Companion Diagnostics market in 2022. Kits & Reagents share of XX%.
Next-Generation Sequencing accounted for XX% of the Companion Diagnostics market in 2022. In Situ Hybridization accounts for XX%.

For competitive landscape, prominent players with considerable market shares are comprehensively analyzed in this report. With information regarding the concentration ratio and detailed data reflecting the market performance of each player shared, the readers can acquire a holistic view of the competitive situation and a better understanding of their competitors.

As the COVID-19 takes over the world, we are continuously tracking the changes in the markets. We analyzed the impact of the pandemic in detail, along with other key factors, such as macro-economy, regional conflicts, industry related news and policies. Meanwhile, market investment scenario, technology status and developments, supply chain challenges, among other essential research elements are all covered.

Key Factors Considered:
COVID-19
The report describes the market scenario during and post the pandemic in the vision of upstream, major market participants, downstream major customers, etc. Other aspects, such as changes in consumer behavior, demand, transport capacity, trade flow under COVID-19, have also been taken into consideration during the process of the research.

Regional Conflict / Russia-Ukraine War
The report also presents the impact of regional conflict on this market in an effort to aid the readers to understand how the market has been adversely influenced and how it's going to evolve in the years to come.

Challenges & Opportunities
Factors that may help create opportunities and boost profits for market players, as well as challenges that may restrain or even pose a threat to the development of the players, are revealed in the report, which can shed a light on strategic decisions and implementation.

The life sciences industry grows and continues to advance, driving innovation and improving healthcare outcomes for individuals around the world.

Artificial Intelligence (AI) and Machine Learning (ML): AI and ML technologies are increasingly being employed in life sciences research and development. They aid in drug discovery, optimizing clinical trials, analyzing vast amounts of biological data, and identifying patterns that can lead to breakthroughs in understanding diseases and developing new therapies.

Digital Health Technologies: Digital health technologies have seen rapid growth, especially in areas like telemedicine, wearable devices, and mobile health applications. These technologies enable remote patient monitoring, facilitate better healthcare access, and empower individuals to manage their health more effectively.

Wearable Devices and Remote Monitoring: Wearable devices, such as smartwatches and fitness trackers, have become more sophisticated, enabling continuous monitoring of vital signs and health parameters. These devices offer opportunities for early detection of health issues and improved management of chronic conditions.

Highlights-Regions

North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Latin America
Brazil
Argentina
Mexico
MEA
Saudi Arabia
UAE
Turkey

Player list
Abbott Laboratories Molecular Inc. (U.S.)
Agilent (Dako Denmark A/S) (U.S.)
ARUP Laboratories Inc. (U.S.)
BioMerieux (France)
Danaher Corporation (Leica Microsystems) (Germany)
Foundation Medicine Inc. (U.S.)
Myriad Genetics Inc. (U.S.)
Roche (Ventana Medical Systems Inc.) (U.S.)
Thermo Fisher Scientific (Life Technologies Corporation) (Germany)
QIAGEN N.V. (Germany)

Types list
Assays
Kits & Reagents
Software & Services

Application list
Next-Generation Sequencing
In Situ Hybridization
Immunohistochemistry
Other Technologies

Table of Content

1 Study Coverage
1.1 Companion Diagnostics Product Introduction
1.2 Global Companion Diagnostics Outlook 2018 VS 2023 VS 2029
1.3 United States Companion Diagnostics Outlook 2018 VS 2023 VS 2029
1.4 Companion Diagnostics Market Size, United States VS Global, 2018-2029
1.4.1 The Market Share of United States Companion Diagnostics in Global, 2018-2029
1.4.2 The Growth Rate of Companion Diagnostics Market Size, United States VS Global, 2018 VS 2023 VS 2029
1.5 Companion Diagnostics Market Dynamics
1.5.1 Companion Diagnostics Market Trends
1.5.2 Companion Diagnostics Market Drivers
1.5.3 Companion Diagnostics Market Challenges
1.5.4 Companion Diagnostics Market Restraints
1.6 Study Objectives
1.7 Years Considered
1.8 Coronavirus Disease (COVID-19) Impact on Global
2 Global Companion Diagnostics Competitor Landscape by Company
2.1 Global Companion Diagnostics Market Size by Company
2.1.1 Top Global Companion Diagnostics Player Ranked by Revenue (2023)
2.1.2 Global Companion Diagnostics Revenue by Player (2018-2023)
2.2 Global Companion Diagnostics Concentration Ratio (CR)
2.2.1 Companion Diagnostics Market Concentration Ratio (CR) (2018-2023)
2.2.2 Global Top 3 and Top 6 Largest Players of Companion Diagnostics in 2023
2.3 Global Companion Diagnostics Business Distribution, Business Type
2.3.1 Global Companion Diagnostics Players, Headquarters and Distribution
2.3.2 Players Companion Diagnostics Business Type
2.3.3 Date of International Players Enter into Companion Diagnostics Market
2.4 Players Mergers & Acquisitions, Expansion Plans
2.5 United States Companion Diagnostics Market Size by Company
2.5.1 Top United States Companion Diagnostics Player s Ranked by Revenue (2023)
2.5.2 United States Companion Diagnostics Revenue by Player (2018-2023)
3 Companion Diagnostics Market Segment by Type
3.1 Companion Diagnostics Market Segment by Type
3.2 Global Companion Diagnostics Market Size by Type
3.3 United States Companion Diagnostics Market Size by Type
4 Companion Diagnostics by Market Segment Application
4.1 Companion Diagnostics Market Segment by Application
4.2 Global Companion Diagnostics Market Size by Application
4.3 United States Companion Diagnostics Market Size by Application
5 Global Companion Diagnostics Market Size by Region
5.1 Global Companion Diagnostics Market Size by Region: 2018 VS 2023 VS 2029
5.2 Global Companion Diagnostics Market Size in Value by Region (2018-2029)
5.2.1 Global Companion Diagnostics Revenue by Region: 2018-2023
5.2.2 Global Companion Diagnostics Revenue by Region: 2023-2029
6 Segment in Regional Level & Country Level
6.1 North America
6.1.1 North America Companion Diagnostics Market Size YoY Growth 2018-2029
6.1.2 North America Companion Diagnostics Market Facts & Figures by Country (2018-2029)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia Pacific
6.2.1 Asia Pacific Companion Diagnostics Market Size YoY Growth 2018-2029
6.2.2 Asia Pacific Companion Diagnostics Market Facts & Figures by Country (2018-2029)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Southeast Asia
6.3 Europe
6.3.1 Europe Companion Diagnostics Market Size YoY Growth 2018-2029
6.3.2 Europe Companion Diagnostics Market Facts & Figures by Country (2018-2029)
6.3.3 Germany
6.3.4 France
6.3.5 UK
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Companion Diagnostics Market Size YoY Growth 2018-2029
6.4.2 Latin America Companion Diagnostics Market Facts & Figures by Country (2018-2029)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Companion Diagnostics Market Size YoY Growth 2018-2029
6.5.2 Middle East and Africa Companion Diagnostics Market Facts & Figures by Country (2018-2029)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 UAE
7 Company Profiles
7.1  Abbott Laboratories Molecular Inc. (U.S.)
7.1.1 Company Details
7.1.2 Description and Business Overview
7.1.3 Companion Diagnostics Introduction
7.1.4 Abbott Laboratories Molecular Inc. (U.S.) Companion Diagnostics Revenue, Gross, and Gross Margin (2018-2023)
7.1.5 Abbott Laboratories Molecular Inc. (U.S.) Recent Development
7.2  Agilent (Dako Denmark A/S) (U.S.)
7.2.1 Company Details
7.2.2 Description and Business Overview
7.2.3 Companion Diagnostics Introduction
7.2.4 Agilent (Dako Denmark A/S) (U.S.) Companion Diagnostics Revenue, Gross, and Gross Margin (2018-2023)
7.2.5 Agilent (Dako Denmark A/S) (U.S.) Recent Development
7.3  ARUP Laboratories Inc. (U.S.)
7.3.1 Company Details
7.3.2 Description and Business Overview
7.3.3 Companion Diagnostics Introduction
7.3.4 ARUP Laboratories Inc. (U.S.) Companion Diagnostics Revenue, Gross, and Gross Margin (2018-2023)
7.3.5 ARUP Laboratories Inc. (U.S.) Recent Development
7.4  BioMerieux (France)
7.4.1 Company Details
7.4.2 Description and Business Overview
7.4.3 Companion Diagnostics Introduction
7.4.4 BioMerieux (France) Companion Diagnostics Revenue, Gross, and Gross Margin (2018-2023)
7.4.5 BioMerieux (France) Recent Development
7.5  Danaher Corporation (Leica Microsystems) (Germany)
7.5.1 Company Details
7.5.2 Description and Business Overview
7.5.3 Companion Diagnostics Introduction
7.5.4 Danaher Corporation (Leica Microsystems) (Germany) Companion Diagnostics Revenue, Gross, and Gross Margin (2018-2023)
7.5.5 Danaher Corporation (Leica Microsystems) (Germany) Recent Development
7.6  Foundation Medicine Inc. (U.S.)
7.6.1 Company Details
7.6.2 Description and Business Overview
7.6.3 Companion Diagnostics Introduction
7.6.4 Foundation Medicine Inc. (U.S.) Companion Diagnostics Revenue, Gross, and Gross Margin (2018-2023)
7.6.5 Foundation Medicine Inc. (U.S.) Recent Development
7.7  Myriad Genetics Inc. (U.S.)
7.7.1 Company Details
7.7.2 Description and Business Overview
7.7.3 Companion Diagnostics Introduction
7.7.4 Myriad Genetics Inc. (U.S.) Companion Diagnostics Revenue, Gross, and Gross Margin (2018-2023)
7.7.5 Myriad Genetics Inc. (U.S.) Recent Development
7.8  Roche (Ventana Medical Systems Inc.) (U.S.)
7.8.1 Company Details
7.8.2 Description and Business Overview
7.8.3 Companion Diagnostics Introduction
7.8.4 Roche (Ventana Medical Systems Inc.) (U.S.) Companion Diagnostics Revenue, Gross, and Gross Margin (2018-2023)
7.8.5 Roche (Ventana Medical Systems Inc.) (U.S.) Recent Development
7.9  Thermo Fisher Scientific (Life Technologies Corporation) (Germany)
7.9.1 Company Details
7.9.2 Description and Business Overview
7.9.3 Companion Diagnostics Introduction
7.9.4 Thermo Fisher Scientific (Life Technologies Corporation) (Germany) Companion Diagnostics Revenue, Gross, and Gross Margin (2018-2023)
7.9.5 Thermo Fisher Scientific (Life Technologies Corporation) (Germany) Recent Development
7.10  QIAGEN N.V. (Germany)
7.10.1 Company Details
7.10.2 Description and Business Overview
7.10.3 Companion Diagnostics Introduction
7.10.4 QIAGEN N.V. (Germany) Companion Diagnostics Revenue, Gross, and Gross Margin (2018-2023)
7.10.5 QIAGEN N.V. (Germany) Recent Development
8 Value Chain and Sales Channels Analysis
8.1 Companion Diagnostics Value Chain Analysis
8.2 Companion Diagnostics Customers
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology
10.1.1 Research Process
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Legal Disclaimer

FAQ's

What does the report cover (Scope)?

It contains all the geographic trends, and market analysis for global market

ENTER REPORT NAME TO SEARCH

Global and United States Companion Diagnostics Market Report & Forecast 2023-2029

Report Summary

Table of Contents

FAQ's

What does the report cover (Scope)?